The Indonesian regulations seemed straightforward until we dug deeper. A Fortune Global 500 client was planning their market entry strategies, confident they had ticked all the regulatory compliance boxes. However, the reality on the ground was far more complex. The official pharma regulation stated one thing, but the unwritten rules of implementation at the National […]
Vietnam's pharmaceutical industry and healthcare sectors are no longer just growing; they are consolidating. In recent years, mergers and acquisitions (M&A) have shifted from a niche option to a primary catalyst shaping market entry strategy, distribution networks, and manufacturing capacity.
Three landmark deals illustrate this transformation. The acquisition of a controlling stake in Imexpharm by China-based Livzon Pharmaceutical Group, Sanofi’s strategic partnership with VNVC to build a massive vaccine facility, and Dongwha Pharm’s entry into the retail space via Trung Sơn Pharma are not isolated events.
These big deals, with significant deal values, signal a new era for foreign investors and a strategic realignment in one of Southeast Asia's most dynamic healthcare markets.
Key Takeaways:
- M&A as an Accelerator: Mergers and acquisitions have become the preferred strategy for foreign investors to bypass the lengthy process of greenfield entry, providing immediate access to manufacturing licenses and established brand equity.
- Consolidation Across the Value Chain: Recent transactions show a clear trend of consolidation in three key areas: generic drugs manufacturing, vaccine production, and pharmacy retail chains.
- Vietnam's Rise as a Regional Hub: Strategic investment is positioning Vietnam not just as a consumer market but as a critical production hub, enhancing its increasing attractiveness to global players.
- Cross-Border Capital is Driving Modernization: Capital from international investors is fueling technology upgrades, facility expansions, and higher competitive standards across the pharmaceutical industry.
- Strategic Partnerships Complement Acquisitions: The market is evolving beyond traditional takeovers, with strategic partnerships creating new production capabilities and reshaping long-term public health infrastructure.
Why M&A is a Preferred Market Entry Strategy
For foreign pharmaceutical companies, entering Vietnam's pharmaceutical market via a greenfield investment presents significant challenges. These include navigating strict compliance with GMP regulations, lengthy product registration timelines, and complex licensing for pharmacy networks. This slow time-to-market can delay profits and ROI for years. Our analysis of ASEAN market entry trends confirms that M&A has emerged as a powerful solution.
An acquisition provides immediate, tangible assets: facilities that meet EU GMP standards, established distribution channels, and a trusted brand.
The recent Imexpharm deal is a prime example. According to Cafef (2025), the deal saw the Chinese conglomerate spend over 5,700 billion VND to acquire a 64.81% ownership stake, granting it direct entry into an extensive generics manufacturing base. Similarly, acquiring a pharmacy chain, as seen with Dongwha and Trung Sơn, represents the fastest way for pharmaceutical companies to build a nationwide retail footprint in the Vietnamese market.
Major M&A Deals Reshaping Vietnam’s Market
Three recent, high-profile transactions offer a clear view into the forces reshaping M&A in pharmaceutical markets within Vietnam. Each deal targets a different segment of the industry, yet all point toward a more consolidated and competitive future for all companies.
Livzon Acquires Imexpharm (Manufacturing)
In a landmark transaction with a deal value of approximately 220 million US dollars, China's Livzon acquired a controlling 64.81% stake in Imexpharm, one of Vietnam's leading Vietnamese pharmaceutical companies. This acquisition provides the company with a significant capital injection and access to advanced technology. While initially sparking debate, the deal is now seen as a strategic move to unlock long-term growth for its portfolio of pharmaceuticals.
Sanofi and VNVC Launch Vaccine Plant (Production Partnership)
Moving beyond a traditional acquisition, French multinational Sanofi partnered with VNVC to build a state-of-the-art vaccine factory focused on biological products. An article from VnExpress (2025) reports the investment is around $77 million, with the facility designed to produce up to 100 million doses annually. This strategic partnership signals Vietnam’s rising role as a regional vaccine production hub.
Dongwha Pharm Acquires Trung Sơn Pharma (Retail)
South Korea’s Dongwha Pharm entered Vietnam’s competitive pharmacy retail space by acquiring a 51% ownership stake in Trung Sơn Pharma for 30 million dollars. Doanhnhan.baophapluat.vn (2025) highlights that the deal targets Trung Sơn’s long-standing reputation and provides the capital to expand its network to 460 stores by 2026.
This move intensifies competition among major pharmacy chains and accelerates the modernization of the retail pharma sector.
What These Deals Reveal About Vietnam’s Transformation
These three transactions, occurring across different industries within healthcare, are not coincidental. They reveal powerful, overarching trends: foreign investors are accelerating the modernization and consolidation of Vietnam's pharmaceutical industry.
The investment from international investors underscores strong momentum in cross-border acquisitions. This influx of capital is raising standards, funding the expansion of larger pharmacy chains, and elevating Vietnam’s production capacity. The Sanofi-VNVC partnership, for example, demonstrates that the country is increasingly viewed as a strategic hub for addressing regional healthcare needs, not just a domestic market to be served.
Opportunities and Risks for Investors
While the momentum is strong, a successful M&A strategy requires a clear-eyed assessment of both the new opportunities and the inherent risk factors.
Opportunities for Investors
- Accelerated Market Entry: Bypass regulatory delays and gain immediate operational capabilities.
- Access to Established Networks: Acquire existing distribution channels and brand recognition.
- Technology Transfer: Inject advanced technology and operational best practices into local businesses.
- Capital for Expansion: Provide the acquired company with the financial resources needed to scale production and expand their portfolio of drugs.
Navigating Potential Risks
- Cross-Cultural Integration: Merging different corporate cultures after an acquisition is a significant challenge in cross-border deals.
- Brand Dilution Concerns: As the initial debate around the Imexpharm transaction showed, there can be local concerns about foreign ownership of established Vietnamese brands.
- Intensified Competition: The consolidation of pharmacy retail is creating a highly competitive environment for all companies in the pharma industry.
Outlook and Next Steps
The recent wave of high-profile deals is not a temporary spike but a clear indicator of a long-term structural shift. From 2025 to 2030, continued growth is expected for Vietnam's pharmaceutical industry, with more deals intensifying consolidation. Pharmaceutical companies, including biopharma companies and other life sciences companies, will continue to attract capital.
For investors investing in Vietnam, M&A will remain a core pathway for the development of their businesses. The key is to move beyond a simple deal value analysis and develop a comprehensive strategy that accounts for post-merger integration and the increasingly competitive landscape.
As the market matures, the focus may shift to specialized areas like oncology or even early-stage research into fields like biotechnology. Understanding these dynamics is the first step toward structuring a successful investment in one of Asia’s most promising pharmaceutical markets.
Frequently Asked Questions
Is M&A the most effective way to enter Vietnam's pharmaceutical market?
For many foreign investors, yes. M&A offers a significant speed-to-market advantage by bypassing the complex and time-consuming process of greenfield licensing and construction. It provides immediate access to manufacturing facilities, established brands, and distribution networks for drugs, which can take years to build.
How long does a typical pharma M&A deal take to complete in Vietnam?
The timeline can vary based on the target company and other factors, but from our experience, a mid-sized deal typically takes 9 to 18 months. This includes navigating regulatory approvals from the Ministry of Planning and Investment and sector-specific requirements from the Ministry of Health, and the mandatory notification of economic concentration to the Vietnam Competition Commission (VCC).
What is the biggest non-financial risk in a cross-border pharma acquisition in Vietnam?
Post-merger integration is often the greatest risk. Successfully merging a foreign corporate culture with a local Vietnamese company requires a deep understanding of different management styles. A poorly executed integration plan can decrease the value of the deal and undermine the strategic goals of the acquisition.
You may also like: Vietnam Pharmaceutical Investment Policies: A New Era For Foreign Investment
